Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)

Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study) is a phase 2, randomised interventional study registered as NCT07381400 by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, with a registry enrolment figure of 128 participants, started 2026-02-01 and due to reach its primary completion in 2028-02-01. Interventions recorded: mFOLFOX6; Serplulimab. Conditions listed: Rectal Cancer. Primary outcome: Pathological Complete Response Rate (pCR). Colorectal eligibility wording from the registry: "Rectal cancer patients with MRI showing the lower edge of the tumor within 15 cm of the anal verge, cT3-4 N any or cT any N1/2;". No results are recorded here; the registry entry is the source.